Effects of methyl prednisolone in early ARDS
Authors:
- Nasef Abdelsalam RezkNRNasef Abdelsalam Rezk
- Amer Mohamed IbrahimAIAmer Mohamed Ibrahim
Open Access
- 1 January 2013
- journal article
- Published by Medknow in The Egyptian Journal of Chest Diseases and Tuberculosis
- Vol. 62 (1) , 167-172
Abstract
IntroductionGlucocorticoid induced down-regulation of systemic inflammation in ARDS is associated with a significant improvement in pulmonary and extrapulmonary organ dysfunction and a reduction in duration of mechanical ventilation and ICU length of stay [1].We aimed in this study to evaluate the effect of methyl prednisolone when used early in ARDS.Patients and methodsWe studied 27 patients with ARDS, we divided them randomly into two groups the first group consists of 18 patients received methyl prednisolone and the other group consists of 9 patients did not receive it. All patients were subjected daily to: history taking and clinical examination, Chest X-ray, routine blood investigation (CBC–LFT–RFT–electrolytes), ABG, Serum lactate, INR, fibrinogen, and aptt, CRP, protein C, protein S, and D-dimer at the beginning and at the end of study.ResultsAfter 7days there were significant improvements of clinical parameters (pulse, temperature, and systolic blood pressure), peep (one parameter from lung injury score), lactate, D-dimer, AST, and a highly significant improvement of creatinine in the methyl prednisolone group when compared to the control group. After 14days from starting treatment there were significant improvements of clinical parameters (pulse and systolic BP), ventilator parameters (FIO2, peep, and RR), systemic inflammation markers organ functions (O2sat, lactate, creatinine, WBCs, AST, and GGT) and CRP. And a significant improvement of CX-ray, earlier extubation from mechanical ventilation and improvement of mortality in the methyl prednisolone group when compared with the control group.ConclusionWe conclude that methyl prednisolone when used on first 2days in ARDS patients improves the LIS, decreases the systemic inflammation, earlier extubation from mechanical ventilation, and decreases the incidence of hospital acquired infectionKeywords
This publication has 9 references indexed in Scilit:
- Methylprednisolone Infusion in Early Severe ARDSChest, 2007
- Nuclear Factor-ĸB- and Glucocorticoid Receptor α- Mediated Mechanisms in the Regulation of Systemic and Pulmonary Inflammation during Sepsis and Acute Respiratory Distress SyndromeNeuroimmunomodulation, 2005
- Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury*Critical Care Medicine, 2005
- Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysisBMJ, 2004
- Protein C and thrombomodulin in human acute lung injuryAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2003
- Host Defense Response and Outcome in ARDSChest, 1997
- The American-European Consensus Conference On Ards. Definitions, Mechanisms, Relevant Outcomes, And Clinical Trial CoordinationAmerican Journal of Respiratory and Critical Care Medicine, 1994
- An Early Test of Survival in Patients with the Adult Respiratory Distress SyndromeChest, 1989
- An Expanded Definition of the Adult Respiratory Distress SyndromeAmerican Review of Respiratory Disease, 1988